Press Releases

03.08.2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

03.02.2022

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women

03.01.2022

Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints

02.28.2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.25.2022

Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment

02.22.2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference

02.15.2022

Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency

02.15.2022

European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults

02.14.2022

Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea

02.11.2022

Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age

02.09.2022

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.08.2022

Pfizer Reports Fourth-Quarter and Full-Year 2021 Results